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Abstract 
We conducted an open-label, prospective, randomized trial to assess the efficacy and safety 
of RANKL inhibition with denosumab to prevent the loss of BMD in the first year after kidney 
transplantation. Ninety kidney transplant recipients were randomized 1:1 two weeks after 
surgery to receive denosumab (60 mg at baseline and 6 months) or no treatment. After 12 
months, total lumbar spine aBMD increased by 4.6% (95% CI 3.3-5.9%) in 46 patients in the 
denosumab group and decreased by -0.5% (95% CI -1.8-0.9%) in 44 patients in the control 
group (between-group difference 5.1% (95% CI 3.1-7.0%), P<0.0001). Denosumab also 
increased aBMD at the total hip by 1.9% (95% CI, 0.1 to 3.7%; P=0.035) over that in the 
control group at 12 months. HR-pQCT in a subgroup of 24 patients showed that denosumab 
increased vBMD at the distal tibia and radius (all P<0.05). Biomarkers of bone turnover (β-
CTX, P1NP) markedly decreased with denosumab (all P<0.0001). Episodes of cystitis and 
asymptomatic hypocalcemia occurred more often with denosumab, whereas graft function, 
rate of rejections and incidence of opportunistic infections were similar. In conclusion, 
denosumab increased BMD in the first year after kidney transplantation but was associated 
with more frequent episodes of urinary tract infection. 
 
Introduction 
Patients with progressing chronic kidney disease develop significant alterations in bone and 
mineral metabolism, including renal osteodystrophy, osteomalacia, adynamic bone disease 
and decreased bone mineralization (1). Kidney transplant candidates often present with 
osteopenia or osteoporosis which aggravate further following kidney transplantation, 
particularly within the first 6 to 12 months after engrafting (2). This leads to a 3-fold increase 
in the risk for fractures and contributes to long-term morbidity after kidney transplantation 
and reduced quality of life (3). 
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The post-transplant loss of bone mass is mainly caused by the immunosuppressive 
treatment, particularly corticosteroids which often cannot be avoided, and by persisting 
hyperparathyroidism which causes phosphate wasting by the functioning graft (4). 
Therapeutic options to limit bone loss include generous supplementation with calcium and 
vitamin D (5, 6), but their use is limited in transplant recipients with persistent 
hyperparathyroidism and hypercalcemia. Although bisphosphonates improve bone loss (7-
10), their use has not become widespread, particularly because of concerns regarding their 
nephrotoxicity, and because of controversial data on their efficacy in preventing fractures in 
renal transplant recipients (11, 12). Furthermore, bisphosphonates have been associated 
with the occurrence of atypical fractures in this patient population (13, 14). Thus, the 
management of bone loss and osteoporosis after kidney transplantation remains 
unsatisfactory, and alternative approaches are needed to prevent the occurrence of fractures 
and the associated morbidity. 
Denosumab is a fully human monoclonal antibody against Receptor Activator of Nuclear 
Factor κB Ligand (RANKL), which was developed for treatment of osteoporosis and 
prevention of fractures (15). By inhibiting the development and the activity of osteoclasts, 
denosumab decreases bone resorption and increases bone density. Compared with 
bisphosphonates, denosumab proved to have superior efficacy in improving BMD and 
preventing fractures in post-menopausal women with osteoporosis (16, 17). Since current 
treatment options for post-transplant bone loss are limited, we studied the efficacy and 
safety of RANKL inhibition with denosumab in de novo kidney transplant recipients. 
Materials and Methods 
This study was a 1-year prospective single-center, randomized, parallel-group, open-label 
clinical trial in de novo kidney transplant recipients, performed in an academic setting at the 
University Hospital Zürich (Switzerland). The sponsor of the study was the University 
Hospital Zürich and the University of Zürich. The study conformed to the principles of the 
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Declaration of Helsinki and the Declaration of Istanbul as outlined in the “Declaration of 
Istanbul on Organ Trafficking and Transplant Tourism.” The local Ethics Committee 
approved the study protocol and acknowledged the statistical analysis plan (IRB approval 
number 2011-0032). All patients provided written informed consent before participating. 
Certified external monitors evaluated the course and the quality of the study at regular 
intervals. This trial is registered with ClinicalTrials.gov, NCT01377467. 
Participants and Study Design 
Adult male and female end-stage renal disease patients were eligible for inclusion if 
transplanted up to 28 days ago with a kidney allograft and being treated with standard triple 
immunosuppression including a calcineurin antagonist, mycophenolate and corticosteroids. 
Key exclusion criteria were poor or unstable graft function (creatinine >200 μmol/l), severe 
osteoporosis (T-score below -4.0), severe hyper- or hypoparathyroidism (iPTH >800 or <10 
ng/l), and hypo- or hypercalcaemia (total calcium <1.8 or >2.7 mmol/l). All patients were 
prescribed daily supplements of calcium (1000 mg), and vitamin D (800 IU or more). 
After baseline assessment, male and female subjects were randomly assigned (1:1) to 
receive subcutaneous injections of 60 mg denosumab at baseline and after 6 months, or no 
treatment. The randomization list was generated by the hospital pharmacist with a computer 
algorithm prior to study initiation, using a permuted blocks design with block sizes of 4 and 6. 
Allocation concealment was ensured by the use of sequentially numbered, opaque, sealed 
envelopes. Study physicians and nurses and participants were aware of the allocated group. 
The persons that performed dual-energy x-ray absorptiometry (DXA), high-resolution 
peripheral quantitative computer tomography (HR-pQCT) and biomarker measurements 
were masked to allocation. 
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Study Assessments 
Study visits were performed at baseline and months 0.5, 1, 2, 3, 6 and 12, when clinical and 
routine laboratory values were captured in a secured web-based case report form 
(secuTrial®, interActive Systems). Graft function was assessed by calculating the eGFR with 
the creatinine-based CKD-EPI formula. 
Levels of parathyroid hormone (PTH), 25-(OH)-vitamin D, 1,25-(OH)2-vitamin D, procollagen 
type I N-terminal propeptide (P1NP), bone-specific alkaline phosphatase (BSAP), and β-
isomer of the C-terminal telopeptide of type I collagen (β-CTX) were assessed in serum 
samples at baseline and months 3, 6, and 12. Urine deoxypyridinoline and creatinine were 
measured at baseline, and months 1, 3, 6, and 12. 
Measurements of areal BMD (aBMD) were performed at the lumbar spine and proximal 
femur by DXA at baseline and at 6 and 12 months in all patients, using a bone densitometer 
of the QDR series in array mode (Hologic Discovery®). Quality controls using the Hologic 
spine phantom were performed daily before the first patient scan. Least significant changes 
for a 95% level of confidence at the lumbar spine (L1 – L4) were as follows: root mean 
square standard deviation 0.029 g/cm2, coefficient of variation 0.030, percent coefficient of 
variation 3.04%. 
A subset of 24 consecutively randomized patients underwent volumetric BMD (vBMD) 
examination by HR-pQCT (XtremeCT®, Scano Medical, Switzerland) at baseline and after 12 
months to assess changes in cortical and trabecular bone mineralization and cortical 
thickness at the distal tibia and radius. 
Outcomes 
The primary endpoint was the percentage change in baseline aBMD at the total lumbar 
spine at 12 months. Secondary endpoints included changes in aBMD at total hip and femoral 
neck, and changes in biomarkers of bone turnover. Adverse events (AE) were reported 
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spontaneously and in response to nondirected questioning at each study visit, and were 
coded and graded according to the Common Terminology Criteria for Adverse Events 
(CTCAE). Hypo- and hypercalcemia were defined as an albumin-adjusted calcium level of 
<1.9 and >2.6 mmol/l, respectively. 
Sample Size Estimation 
We calculated that a sample size of 43 patients per group would provide a statistical power 
of 86% to detect a 4% difference in the percentage change of aBMD at the total lumbar 
spine at 12 months, using a two-sided t-test with an α-level of 0.05 and assuming a mean ± 
SD change of 4 ± 6% in the denosumab group and 0 ± 6% in the control group. To account 
for a dropout rate of 5%, it was planned to randomize a total of 90 patients. 
Statistical Analysis 
Analyses of efficacy and safety were based on the intention-to-treat principle. For aBMD 
data, missing values were replaced with a last-observation-carried-forward approach; for all 
other efficacy endpoints, an available case analysis was performed. The primary efficacy 
endpoint, the percentage change in aBMD at the total lumbar spine at 12 months, was 
analyzed using a linear model with treatment as fixed effect and baseline aBMD as 
covariate. 
The exact Wilcoxon rank sum test was used to compare the percentage changes between 
baseline and 12 months for HR-pQCT parameters. Changes of bone mineral and 
metabolism biomarkers and changes of renal function were analyzed using a general linear 
model for repeated measures. 
For the most frequent AE, the number of affected patients was compared between the two 
treatment groups using the chi-square test. The number of bacterial, viral or fungal infections 
was compared between the two treatment groups with the exact Wilcoxon rank sum test. 
Statistical analyses were done using IBM SPSS Statistics Version 20. 
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Results 
Baseline Clinical Characteristics 
The study population included 90 kidney transplant recipients with a functioning graft. 
Patients were recruited from June 20, 2011, to May 2, 2014. Patients were randomized after 
15.7 ± 6.4 days after transplantation to denosumab treatment (n=46) at a dose of 60 mg 
subcutaneously at baseline and at 6 months, or no treatment (n=44). Two patients did not 
receive denosumab and another two patients received only the baseline dose (Figure 1). 
Baseline characteristics were balanced between the two groups, except for more men and a 
correspondingly higher baseline aBMD in the denosumab group (Table 1). All patients 
received triple immunosuppression therapy with a calcineurin inhibitor (70% tacrolimus, 30% 
cyclosporine), mycophenolate and corticosteroids. The cumulative amount of corticosteroids 
over the 12-months study period was similar, amounting to 3.760 ± 1.445 g in the 
denosumab and 3.974 ± 1.727 g in the control group. 
At baseline 45.6% of all patients had osteopenia and 10.0% had osteoporosis. All patients 
were prescribed vitamin D and calcium throughout the study, receiving a daily dose of 1526 
± 946 vs 1400 ± 1295 IU vitamin D and 756 ± 609 vs 619 ± 475 mg calcium at month 12 in 
the denosumab and control group, respectively. During the 12-month study period two 
patients in the denosumab group were initiated on cinacalcet and one on calcitriol. None of 
the patients received paricalcitol, bisphosphonates or other drugs with specific effects on 
bone metabolism. 
Table 2 shows the parameters of renal function and mineral metabolism at baseline, 3, 6 and 
12 months. The eGFR was similar and stable in the two treatment arms. Serum calcium and 
phosphate increased and were similar, whereas PTH decreased more rapidly in the control 
group. The serum levels of 25-(OH)-vitamin D and 1,25-(OH)2-vitamin D progressively 
increased in both groups to similar levels at 12 month. 
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Change in areal Bone Mineral Density 
Denosumab treatment was associated with increased aBMD at all measured sites (Figure 2, 
Table 3 and Table 4). Denosumab increased aBMD over that in the control group at 12 
months at the total lumbar spine by 5.1% (P<0.0001) and at the total hip by 1.9% (P=0.035). 
The effect of denosumab was significant at 6 months at the total lumbar spine (P<0.0001) 
and total hip (P=0.009), but not quite significant at the femoral neck (P=0.064). Denosumab 
also significantly increased the T-scores at the total lumbar spine at 6 and 12 months, and at 
the total hip at 6 months (Table 4). Subgroup analysis revealed that the effect of denosumab 
on lumbar spine aBMD at 12 months was consistent, with slightly better effects in patients 
that were younger and of male sex, and in patients having lower T-scores, higher eGFR, and 
lower PTH levels (Figure 2D). 
In a subgroup of 24 randomized patients, we analyzed vBMD at the distal tibia and radius at 
baseline and 12 months by HR-pQCT (Table 5). Treatment with denosumab was associated 
with a significant increase of the average vBMD and the cortical thickness at both sites. The 
cortical vBMD increased significantly at the tibia, whereas the changes of the trabecular 
vBMD were not significant. 
Change in Biomarkers of Bone Turnover 
Serum and urine levels of biochemical markers of bone resorption and bone formation 
decreased significantly in the denosumab group when compared to the control group (Figure 
3). The between-subjects effect was significant for all biomarkers (P<0.0001 for β-CTX, 
P1NP, and BSAP; P=0.004 for deoxypyridinoline:creatinine ratio). Moreover, the 
time*treatment interaction was significant for β-CTX (P=0.002) and P1NP (P=0.012), 
indicating that the course over time for β-CTX and P1NP was also different in the two study 
arms. Thus, bone turnover decreased significantly in the denosumab group, whereas it 
remained unchanged in the control group. 
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Safety 
All 90 patients had complete follow-up during the 12 month study period. There were 349 
adverse events (AE) in the denosumab (7.6 per patient) and 273 in the control group (6.2 
per patient), of which 60 (17%) and 52 (19%), respectively, were serious adverse events 
(SAE) (Table 6). There were no unexpected AE or SAE and no deaths. Overall, AE were of 
mild or moderate degree and of similar severity in both groups. The most common AE were 
urinary tract infection (cystitis), diarrhea, CMV viremia, cough, leg pain, flu-like disease, and 
polyoma (BK) viremia, which occurred in more than 20% of the patients. Urinary tract 
infections (P=0.008) and diarrhea (P=0.048) occurred in more patients in the denosumab 
than in the control group. In patients with urinary tract infection the spectrum of urine 
bacteria was similar in the denosumab and control group, but E. coli (20/45 vs 9/29 positive 
cultures) and Enterococcus faecalis (8/45 vs 1/29 positive cultures) occurred more frequently 
in the denosumab than in the control group. A total of 146 vs 99 infections were counted in 
the denosumab and the control group, respectively. Patients in the denosumab group thus 
experienced a higher number of infections than patients in the control group (P=0.044). 
Transplant-related AE occurred with similar frequency in both groups, including CMV 
viremia, BK viremia, lymphocele, transplant pyelonephritis, and episodes of acute rejection. 
Renal function remained stable with no difference in serum creatinine, eGFR and proteinuria 
at 12 months. There was one case of graft failure due to BK virus nephropathy and rejection 
in the denosumab group. There was one case of a traumatic rib fracture occurring in a 
patient with osteoporosis in the control group. Episodes of asymptomatic and transient 
hypocalcemia (<1.9 mmol/l) occurred more frequently in the denosumab group (12 vs 1), 
whereas episodes of hypercalcemia (>2.6 mmol/l) were less frequent (37 vs 55). 
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Discussion 
In de novo kidney transplant recipients on corticosteroid-containing immunosuppression, the 
administration of denosumab significantly increased aBMD at vertebral and non-vertebral 
sites. Denosumab also improved cortical vBMD and cortical thickness at the distal tibia and 
radius. As such denosumab differs from other drugs such as bisphosphonates, which so far 
failed to demonstrate any positive effect on cortical bone. Furthermore denosumab 
significantly decreased the levels of blood and urine biomarkers of bone turnover. The 
beneficial effects of denosumab appeared robust and were seen in all subgroups. 
Patients with end-stage renal disease presenting for kidney transplantation often have a 
reduced bone mass and an increased risk for fracture, particularly if they had previous 
corticosteroid treatment for glomerulonephritis or if they had long-standing secondary 
hyperparathyroidism (1, 2, 4). Kidney transplantation is associated with a further loss of bone 
mass of up to 10% in the first year after grafting (14, 18), although more recent studies - and 
our study as well - documented less bone loss, possibly because of a lower use of 
corticosteroids and an increased use of calcium and vitamin D supplementation (1, 2, 12, 
19). Patients with heightened risk for rejection, however, may not qualify for corticosteroid-
free immunosuppression and need alternative approaches to preserve their bone mass. 
Follow-up studies of transplant recipients have documented that one in five patients 
develops a fracture within five years after transplantation (20, 21). Several therapeutic 
schemes were shown to prevent the loss of bone mass and to possibly improve the fracture 
risk in transplant recipients, including supplementation with calcium and/or vitamin D and 
treatment with bisphosphonates (12, 22). While calcium and vitamin D supplementation 
improve the first year loss of bone mass in renal transplantation, the addition of a 
bisphosphonate does not appear to increase bone mass at all skeletal sites (6, 10). Whereas 
calcium and vitamin D are therefore often given after transplantation, bisphosphonates are 
not frequently prescribed, particularly because of limited efficacy and the well-known side 
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effects. Paricalcitol and cinacalcet improve persistent hyperparathyroidism after 
transplantation, but these drugs do also not appear to have a major effect on BMD (23-25). 
Thus, despite progress, the management of bone loss after transplantation has remained 
unsatisfactory. 
This study shows that denosumab effectively increased BMD in kidney transplant recipients, 
comparable to its effect in postmenopausal women with osteoporosis and other patient 
groups (16). This suggests that denosumab’s interference with the RANKL system is 
effective in diverse situations of bone loss. In the setting of renal transplantation this does 
not only include effective antagonism of corticosteroid-induced loss of bone mass, but also 
counteracting high-turnover bone disease from persistent hyperparathyroidism. Therefore 
this study extends the spectrum of patients benefiting from RANKL antagonism to kidney 
transplant recipients and potentially to recipients of other organ transplants at high risk of 
osteoporosis and fracture. 
Only limited data are available regarding fracture prevention in kidney transplant recipients. 
In retrospective analyses, corticosteroid minimization was associated with preservation of 
bone mass and a reduction of the fracture risk (19). Whether bisphosphonates decrease the 
fracture risk is debated (11, 12). Given that denosumab reduces the occurrence of fractures 
in osteoporotic patients with chronic renal failure we would predict that it should also be 
effective in preventing fractures in kidney transplant recipients (26), but this would need to 
be examined in appropriately powered studies. 
Our study has limitations, which includes a slight imbalance in patient characteristics 
between the two groups that is likely due to a relatively low sample size. However, subgroup 
analysis revealed that the effect of denosumab on aBMD was consistent. From a conceptual 
point of view the treatment duration and the follow-up were short, wherefore the study could 
not address the risk of fracture. This would obviously require a much larger patient number 
and prolonged treatment time, but this was not the scope of the present study. Also, it might 
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be argued that treatment with denosumab could increase the risk for low-turnover bone 
disease, as seen in patients with renal failure after extended treatment with active vitamin D, 
calcium-containing phosphate binders or bisphosphonates (27, 28), and also in patients with 
a renal transplant (29). Since we did not perform bone biopsies we could not firmly assess 
whether denosumab promoted low-turnover bone disease. However, the profiles and the 
levels of the biomarkers of bone resorption (β-CTX and urine deoxypyridinoline) and bone 
formation (P1NP and BSAP) showed that bone turnover was not entirely suppressed with 
denosumab treatment, but rather improved towards normal levels. Persistent 
hyperparathyroidism may possibly counteract the development of low-turnover bone disease 
in denosumab-treated kidney transplant recipients. From a general point of view it may be 
argued that an increase in BMD in renal transplant patients as measured by DXA or HR-
pQCT may not necessarily translate into a subsequent reduction of fracture risk. On the 
other hand denosumab-induced increases in BMD have been shown to correlate very well 
with a reduced fracture risk in various patient populations, including patients with renal 
failure (26). 
Urinary tract infections are common in kidney transplant recipients (30). Treatment with 
denosumab was associated with an increase of the incidence of these infections in our 
study. Patients mainly developed cystitis which responded rapidly to antibiotic treatment; the 
incidence of pyelonephritis and urosepsis was not increased. A slightly higher number of 
infections of the renal and urinary system has previously been noticed in denosumab-treated 
postmenopausal women (31). The RANKL system may play a role in specific and non-
specific immune responses, and the inhibition of RANKL by denosumab might influence the 
resistance to microbial organisms, however at this point the mechanisms which could 
explain the increased incidence of urinary tract infections remain unclear (32, 33). 
In conclusion, denosumab significantly increased BMD at all measured skeletal sites and 
reduced biomarkers of bone turnover in kidney transplant recipients. Except for a higher 
number of urinary tract infections and asymptomatic episodes of hypocalcemia, denosumab 
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was safe. Denosumab treatment may therefore be useful to improve bone health in the first 
year after kidney transplantation. 
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Figure Legends 
Figure 1: Study flow chart 
Figure 2: Within-group change in aBMD (%) from baseline to 6 months and to 12 months by 
DXA at total lumbar spine (A), total hip (B) and femoral neck (C). Data are least-squares 
means adjusted for baseline aBMD, error bars indicate 95% CI. *** P<0.0001, ** P <0.01, * P 
<0.05. Forest plot (D), showing least-squares means and 95% CI for primary endpoint (% 
change in aBMD at the total lumbar spine at 12 months), stratified for age, sex, baseline T-
score, baseline GFR and baseline PTH. Numbers in brackets show number of patients. 
aBMD, areal bone mineral density; DXA, dual-energy x-ray absorptiometry; GFR, glomerular 
filtration rate. 
Figure 3: Course of serum β-CTX (A), serum P1NP (B), urine deoxypyridinoline to creatinine 
ratio (C) and serum BSAP (D) from baseline to month 12 in the control and denosumab 
group. Data are least-squares means, and error bars indicate 95% CI. Analyses include 
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patients with valid data at all timepoints. Thus for β-CTX 42 and 42 patients, for P1NP 41 
and 42 patients, for urine deoxypyridinoline:creatinine ratio 25 and 21 patients, and for BSAP 
41 and 42 patients from the control and denosumab group, respectively, were included. β-
CTX, C-terminal telopeptide of type I collagen; BSAP, bone-specific alkaline phosphatase; 
P1NP, procollagen type I N-terminal propeptide. 
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Table 1: Baseline characteristics of patients 
 Control (n=44) Denosumab (n=46) 
Age (years) 49.0 ± 12.9 50.0 ± 14.0 
Men 22 (50.0%) 35 (76.1%) 
White ethnicity 42 (95.5%) 44 (95.7%) 
Body-mass index (kg/m2) 25.5 ± 5.3 25.8 ± 4.6 
Pre-transplant dialysis mode   
Hemodialysis 31 (70.5%) 26 (56.5%) 
Peritoneal dialysis 9 (20.5%) 7 (15.2%) 
Pre-emptive transplantation 4 (9.1%) 13 (28.3%) 
Repeat transplantation 7 (15.9%) 7 (15.2%) 
Transplant from deceased donor 26 (59.1%) 18 (39.1%) 
Number of HLA mismatches 3.8 ± 1.3 3.5 ± 1.3 
Panel reactive antibody titer ≥20% 0 (0.0%) 0 (0.0%) 
Cause of end-stage renal disease   
Chronic glomerulonephritis 11 (25.0%) 19 (41.3%) 
Diabetic nephropathy 3 (6.8%) 4 (8.7%) 
Hypertensive/vascular nephropathy 6 (13.6%) 2 (4.3%) 
Polycystic kidney disease 8 (18.2%) 12 (26.1%) 
Other hereditary 4 (9.1%) 1 (2.2%) 
Other 12 (27.3%) 8 (17.4%) 
Immunosuppression   
Induction therapy † 44 (100.0%) 45 (97.8%) 
Tacrolimus 33 (75.0%) 30 (65.2%) 
Cyclosporine 11 (25.0%) 16 (34.8%) 
Mycophenolate 44 (100.0%) 46 (100.0%) 
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Corticosteroids 44 (100.0%) 46 (100.0%) 
Areal bone mineral density (aBMD) and T-scores   
Total lumbar spine aBMD (g/cm2) 0.934 ± 0.129 1.002 ± 0.139 
Total lumbar spine T-score 
-1.27 ± 1.15 -0.67 ± 1.25 
Total hip aBMD (g/cm2) 0.847 ± 0.092 0.925 ± 0.132 
Total hip T-score 
-1.05 ± 0.65 -0.59 ± 0.97 
Number of osteopenic patients 25 (56.8%) 16 (34.8%) 
Number of osteoporotic patients 6 (13.6%) 3 (6.5%) 
 
Data are mean ± SD or number (%). † Patients received basiliximab (68.9%) or anti-
thymocyte globulin (30.0%). aBMD, areal bone mineral density. 
 
Table 2: Parameters of renal function and mineral metabolism 
Parameter Visit Control  Denosumab  P-values 
    
within-subjects 
effect 
between-
subjects effect 
eGFR (ml/min/1.73 m2) 
n=44 (control), n=44 (denosumab) 
Baseline 54.2 ± 16.2 53.5 ± 15.4 
0.704 0.820 
3 months 52.9 ± 15.1 56.0 ± 17.2 
6 months 55.0 ± 15.3 54.2 ± 17.9 
12 months 55.2 ± 20.7 56.4 ± 17.4 
 
Calcium (mmol/l) 
n=42 (control), n=39 (denosumab) 
Baseline 2.33 ± 0.22 2.31 ± 0.16 
<0.001 0.198 
3 months 2.47 ± 0.19 2.40 ± 0.21 
6 months 2.47 ± 0.17 2.46 ± 0.15 
12 months 2.52 ± 0.16 2.47 ± 0.15 
 
Phosphate (mmol/l) 
n=41 (control), n=40 (denosumab) 
Baseline 0.57 ± 0.18 0.58 ± 0.23 
<0.001 0.890 
3 months 0.76 ± 0.16 0.78 ± 0.33 
6 months 0.83 ± 0.19 0.82 ± 0.28 
12 months 0.89 ± 0.18 0.85 ± 0.37 
 
25-(OH)-vitamin D (μg/l) 
n=40 (control), n=41 (denosumab) 
Baseline 18.1 ± 9.0 17.4 ± 8.3 
<0.001 0.578 
3 months 22.9 ± 7.1 21.6 ± 5.9 
6 months 
  26.7 ± 11.6 24.4 ± 7.1 
12 months 28.4 ± 8.9 28.5 ± 8.2 
 
1,25-(OH)2-vitamin D (ng/l) 
n=34 (control), n=36 (denosumab) 
Baseline 34.2 ± 24.6 29.6 ± 21.0 
<0.001 0.607 
3 months 55.3 ± 14.5 60.5 ± 29.7 
6 months 58.1 ± 22.5 54.2 ± 21.4 
12 months 51.5 ± 20.0 47.2 ± 23.7 
 
PTH (ng/l) 
n=40 (control), n=40 (denosumab) 
Baseline 
  147.3 ± 141.6   163.1 ± 157.9 
<0.001 0.114 
3 months 111.6 ± 85.4   173.6 ± 175.5 
6 months 
  99.4 ± 64.7   157.0 ± 167.4 
12 months 100.7 ± 67.3 106.7 ± 69.7 
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Course of renal function (eGFR as determined by the CKD-EPI formula) and blood 
parameters of mineral metabolism at baseline, 3, 6 and 12 months. Data are mean ± SD. 
PTH was the only parameter with a significant time*treatment interactions (P=0.047). 
Adjustment for multiplicity was not performed. eGFR, estimated glomerular filtration rate; 
PTH, parathyroid hormone.  
 
Table 3: Between-group differences in aBMD (%) and T-scores by DXA 
 
Change from baseline B SE 95% CI P Values
Lumbar spine aBMD     
   Month 6 4.6 0.8 3.0 – 6.2 <0.0001 
   Month 12 5.1 1.0 3.1 – 7.0 <0.0001 
Lumbar spine T-score  
   Month 6 0.39 0.07 0.24 – 0.53 <0.0001 
   Month 12 0.42 0.08 0.26 – 0.59 <0.0001 
Total hip aBMD  
   Month 6 1.8 0.7 0.4 – 3.1 0.009 
   Month 12 1.9 0.9 0.1 – 3.7 0.035 
Total hip T-score     
   Month 6 0.10 0.04 0.01 – 0.18 0.028 
   Month 12 0.10 0.05 -0.01 – 0.20 0.075 
Femoral neck aBMD  
   Month 6 2.0 1.1 -0.1 – 4.2 0.064 
   Month 12 1.1 1.2 -1.3 – 3.4 0.380 
Femoral neck T-score  
   Month 6 0.10 0.07 -0.04 – 0.23 0.152 
   Month 12 0.02 0.07 -0.12 – 0.17 0.738 
Between-group differences (denosumab – control) in aBMD (percentage) and T-scores from 
baseline to 6 and to 12 months, adjusted for baseline aBMD and T-score, respectively. Data 
are least-squares means and 95% CI. B, regression coefficients; SE, standard errors of the 
regression coefficients. N=44 (control) and n=46 (denosumab) for aBMD; n=43 (control) and 
n=43 (denosumab) for T-scores. Adjustment for multiplicity was not performed. aBMD, areal 
bone mineral density; DXA, dual-energy x-ray absorptiometry. 
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Table 4: Within-group changes in aBMD (%) and T-scores by DXA 
 
Parameter   
DXA Control (n=44) Denosumab (n=46) P Values
Total lumbar spine aBMD (g/cm2)    
   Change from baseline to 6 months 
-1.6 (-2.7 – -0.5) 3.0 (1.9 – 4.1) <0.0001 
   Change from baseline to 12 months 
-0.5 (-1.8 – 0.9) 4.6 (3.3 – 5.9) <0.0001 
Total lumbar spine T-score    
   Change from baseline to 6 months 
-0.13 (-0.23 – -0.03) 0.25 (0.16 – 0.35) <0.0001 
   Change from baseline to 12 months 
-0.02 (-0.14 – 0.10) 0.40 (0.28 – 0.52) <0.0001 
 
Total hip aBMD (g/cm2)    
   Change from baseline to 6 months 
-0.3 (-1.2 – 0.6) 1.4 (0.5 – 2.3) 0.009 
   Change from baseline to 12 months 0.4 (-0.8 – 1.7) 2.3 (1.1 – 3.5) 0.035 
Total hip T-score    
   Change from baseline to 6 months 
-0.01 (-0.07 – 0.05) 0.09 (0.03 – 0.15) 0.028 
   Change from baseline to 12 months 0.04 (-0.03 – 0.12) 0.14 (0.07 – 0.22) 0.075 
 
Femoral neck spine aBMD (g/cm2)    
   Change from baseline to 6 months 
-0.9 (-2.4 – 0.6) 1.1 (-0.3 – 2.6) 0.064 
   Change from baseline to 12 months 0.4 (-1.2 – 2.1) 1.5 (-0.1 – 3.1) 0.380 
Femoral neck T-score    
   Change from baseline to 6 months 
-0.05 (-0.14 – 0.05) 0.05 (-0.04 – 0.14) 0.152 
   Change from baseline to 12 months 0.03 (-0.07 – 0.13) 0.05 (-0.05 – 0.15) 0.738 
 
Within-group changes in aBMD (percentage) and T-scores from baseline to 6 and to 12 
months. Data are least-squares means and 95% CI. P values indicate significance for 
between-group differences. Adjustment for multiplicity was not performed. aBMD, areal bone 
mineral density; DXA, dual-energy x-ray absorptiometry. 
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Table 5: Effect of denosumab on changes in vBMD and cortical thickness by HR-
pQCT 
 
HR-pQCT Control (n=14) Denosumab (n=10) P Values
Distal tibia 
   
Average vBMD 
-0.3 (-3.3 – 2.7) 2.2 (0.7 – 3.2) 0.019 
   Cortical vBMD 
-0.5 (-2.0 – 0.1) 0.1 (-0.5 – 1.4) 0.042 
   Trabecular vBMD 1.1 (-2.5 – 4.1) 1.8 (1.3 – 4.2) 0.371 
Cortical thickness 
-0.9 (-5.9 – 1.6) 2.8 (1.4 – 8.0) 0.005 
Distal radius 
   
Average vBMD 
-1.6 (-5.2 – 0.7) 1.3 (-1.9 – 2.2) 0.031 
   Cortical vBMD 
-0.9 (-2.7 – 0.4) -0.1 (-1.8 – 1.3) 0.212 
   Trabecular vBMD 0.2 (-9.4 – 3.1) 2.4 (1.1 – 4.1) 0.108 
Cortical thickness 
-3.6 (-7.7 – -1.3) 0.9 (-6.0 – 2.0) 0.048 
 
Percentage change in vBMD (mg HA/cm3) and cortical thickness (mm). Data show median 
and 95% CI based on quantiles of the binomial distribution. Adjustment for multiplicity was 
not performed. vBMD, volumetric bone mineral density. 
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Table 6: Adverse events in the safety analysis population 
 
Adverse events Control group (n=44) Denosumab group (n=46) 
 No. events (%) No. patients (%) No. events (%) No. patients (%) 
Urinary tract infection** 25 (9.2%) 11 (25.0%) 51 (14.6%) 24 (52.2%) 
Transplant 
pyelonephritis 
5 (1.8%) 5 (11.4%) 3 (0.9%) 3 (6.5%) 
Diarrhea* 14 (5.1%) 13 (29.5%) 32 (9.2%) 23 (50.0%) 
CMV viremia 24 (8.8%) 18 (40.9%) 26 (7.4%) 20 (43.5%) 
Cough 19 (7.0%) 12 (27.3%) 9 (2.6%) 7 (15.2%) 
Leg pain 12 (4.4%) 9 (20.5%) 14 (4.0%) 9 (19.6%) 
Flu-like disease 14 (5.1%) 12 (27.3%) 12 (3.4%) 11 (23.9%) 
Polyoma (BK) viremia 11 (4.0%) 11 (25.0%) 12 (3.4%) 12 (26.1%) 
Abdominal pain 10 (3.7%) 8 (18.2%) 10 (2.9%) 9 (19.6%) 
Leg edema 5 (1.8%) 5 (11.4%) 10 (2.9%) 9 (19.6%) 
Lymphocele 9 (3.3%) 8 (18.2%) 7 (2.0%) 7 (15.2%) 
Herpes labialis 3 (1.1%) 3 (6.8%) 8 (2.3%) 5 (10.9%) 
Acute rejection 4 (1.5%) 3 (6.8%) 5 (1.4%) 5 (10.9%) 
Fracture 1 (0.4%) 1 (2.3%) 0 (0.0%) 0 (0.0%) 
Loss of graft function 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (2.2%) 
Other 117 (42.9%) 36 (81.8%) 149 (42.7%) 42 (91.3%) 
Total 273 (100.0%) 44 (100.0%) 349 (100.0%) 45 (97.8%) 
 
* P=0.048; ** P=0.008 
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